Acetic Acid

Acetic Acid

SCHEMBL1287799

CC(=O)O.CC1CC1

nearest known ligand 0.00

Full drug profile on Sugi Atlas →

Known targets — ChEMBL curated mechanism

ADRA2AADRA2BADRA2CADRB2AGTR1AVPR1AAVPR1BAVPR2BDKRB2CALCRCHRNA3CHRNB4ESR1ESR2GHSRGNRHRGSC1HSPA8MALT1MC1RMC4RNOS1NOS2NOS3OPRK1OXTRRAMP1RAMP2RAMP3SCN5ASSTR1SSTR2SSTR3SSTR4SSTR5dacAdacBdacCfolPftsImrcAmrcBmrdArplArplBrplCrplDrplErplFrplJrplKrplLrplMrplNrplOrplPrplQrplRrplSrplTrplUrplVrplWrplXrplYrpmArpmBrpmCrpmDrpmErpmFrpmGrpmHrpmIrpmJrpsArpsBrpsCrpsDrpsErpsFrpsGrpsHrpsIrpsJrpsKrpsLrpsMrpsNrpsOrpsPrpsQrpsRrpsSrpsTrpsUykgMykgO

The experimentally established mechanism targets of Acetic Acid. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.

⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Acetic Acid SCHEMBL2803174 0.96 FFAR3 (0.50)
Methylcyclopentane SCHEMBL4087874 0.83 EPHX1 (0.44)
Methylcyclopentane SCHEMBL4362497 0.83 EPHX1 (0.44)
SCHEMBL9502832 0.81
Bicarbonate SCHEMBL27382637 0.81 EPHX1 (0.37)
Acetamide SCHEMBL9143780 0.81
Carbamic Acid SCHEMBL11215146 0.81
Methacrylic Acid SCHEMBL3288565 0.81 TDP1 (0.38)
Acetic Acid SCHEMBL938460 0.81 EPHX1 (0.48)
Acetic Acid SCHEMBL4087167 0.81 EPHX1 (0.48)

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 52 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-1283115-A Composition for treating respiratory and skin diseases, comprising at least one leukotriene antagonist and at least one antihistamine SCHERING CORP (US) 2001-02-07 CN claimed
US-10842952-B2 Dry powder inhaler SIMA PATENT VE LISANSLAMA HIZMETLERI LTD. STI. (TR) 2020-11-24 US disclosed
CN-105085428-B Aromatic heterocyclic derivatives and its application on drug 广东东阳光药业有限公司 2019-03-22 CN disclosed
CN-106279138-B Aromatic heterocyclic derivatives and its application in drug 广东东阳光药业有限公司 2019-03-01 CN disclosed
US-20180264211-A1 DRY POWDER INHALER SIMA PATENT VE LISANSLAMA HIZMETLERI LTD. STI. (TR) 2018-09-20 US disclosed
CN-105399698-B Aromatic heterocyclic derivatives and its application in drug 广东东阳光药业有限公司 2018-08-10 CN disclosed
US-9849255-B2 Inhalation device BILGIC MAHMUT (TR) 2017-12-26 US disclosed
EP-2782488-B1 INHALATION DEVICE BILGIC MAHMUT (TR) 2017-10-25 EP disclosed
US-9795750-B2 Dry powder inhaler SIMA PATENT VE LISANSLAMA HIZMETLERI LTD. STI. (TR) 2017-10-24 US disclosed
US-9795751-B2 Dry powder inhaler SIMA PATENT VE LISANSLAMA HIZMETLERI LTD. STI. (TR) 2017-10-24 US disclosed
WO-2011129794-A1 INHALATION DEVICE BILGIC MAHMUT (TR) 2011-10-20 WO disclosed
WO-2011129791-A1 INHALER COMPRISING BLISTER PACKAGE BILGIC MAHMUT (TR) 2011-10-20 WO disclosed
WO-2011129788-A1 USER-FRIENDLY DRY POWDER INHALER BILGIC MAHMUT (TR) 2011-10-20 WO disclosed
WO-2011129789-A1 DRY POWDER INHALER MOUTHPIECE BUTTON BILGIC MAHMUT (TR) 2011-10-20 WO disclosed
WO-2011129786-A1 INHALER USED FOR DELIVERY OF MEDICAMENT IN DRY POWDER FORM BILGIC MAHMUT (TR) 2011-10-20 WO disclosed
WO-2011129795-A1 DRY POWDER INHALER MOUTHPIECE BUTTON BILGIC MAHMUT (TR) 2011-10-20 WO disclosed
WO-2011129793-A1 DRY POWDER INHALER MOUTHPIECE BUTTON BILGIC MAHMUT (TR) 2011-10-20 WO disclosed
WO-2011129785-A1 DRY POWDER INHALER MOUTHPIECE BUTTON BILGIC MAHMUT (TR) 2011-10-20 WO disclosed
CN-1735601-A Combination products with carboxylic acid derivatives that inhibit the binding of integrins to their receptors and other therapeutic compounds SCHERING CORP (US) 2006-02-15 CN disclosed
CN-1283115-A Composition for treating respiratory and skin diseases, comprising at least one leukotriene antagonist and at least one antihistamine SCHERING CORP (US) 2001-02-07 CN disclosed